164 related articles for article (PubMed ID: 9236358)
1. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
Jones DR; Detterbeck FC; Egan TM; Parker LA; Bernard SA; Tepper JE
Ann Thorac Surg; 1997 Jul; 64(1):185-91; discussion 191-2. PubMed ID: 9236358
[TBL] [Abstract][Full Text] [Related]
2. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Bates BA; Detterbeck FC; Bernard SA; Qaqish BF; Tepper JE
J Clin Oncol; 1996 Jan; 14(1):156-63. PubMed ID: 8558191
[TBL] [Abstract][Full Text] [Related]
3. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Wood MD; Zaki BI; Gordon SR; Sutton JE; Lisovsky M; Gui J; Bubis JA; Dragnev KH; Rigas JR
J Thorac Oncol; 2013 Apr; 8(4):487-94. PubMed ID: 23370365
[TBL] [Abstract][Full Text] [Related]
4. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
5. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction.
Posner MC; Gooding WE; Landreneau RJ; Rosenstein MM; Clarke MR; Peterson MS; Lembersky BC
Cancer J Sci Am; 1998; 4(4):237-46. PubMed ID: 9689982
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
8. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
Davies L; Lewis WG; Arnold DT; Escofet X; Blackshaw G; Gwynne S; Evans M; Roberts SA; Appadurai I; Crosby TD
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):578-85. PubMed ID: 20591633
[TBL] [Abstract][Full Text] [Related]
10. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
Vermund H; Pories WJ; Hillard J; Wiley AL; Youngblood R
Acta Oncol; 2001; 40(5):558-65. PubMed ID: 11669326
[TBL] [Abstract][Full Text] [Related]
14. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma.
O'Connor BM; Chadha MK; Pande A; Lombardo JC; Nwogu CE; Nava HR; Yang G; Javle MM
Cancer J; 2007; 13(2):119-24. PubMed ID: 17476140
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma.
Stewart FM; Harkins BJ; Hahn SS; Daniel TM
Cancer; 1989 Aug; 64(3):622-8. PubMed ID: 2501018
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Tepper J; Krasna MJ; Niedzwiecki D; Hollis D; Reed CE; Goldberg R; Kiel K; Willett C; Sugarbaker D; Mayer R
J Clin Oncol; 2008 Mar; 26(7):1086-92. PubMed ID: 18309943
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
19. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Stahl M; Wilke H; Fink U; Stuschke M; Walz MK; Siewert JR; Molls M; Fett W; Makoski HB; Breuer N; Schmidt U; Niebel W; Sack H; Eigler FW; Seeber S
J Clin Oncol; 1996 Mar; 14(3):829-37. PubMed ID: 8622031
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
